Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

23.20 +1.51 (+6.96%)

Official Closing Price Updated: 4:10 PM EST, Jan 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,238,787
Open	21.96
Bid (Size)	21.90 (100)
Ask (Size)	23.10 (500)
Prev. Close	21.69
Today's Range	21.75 - 23.39
52wk Range	6.500 - 26.40
Shares Outstanding	107,100,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

Today 16:05 EST

From Arcus Biosciences

Via Business Wire

Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return ↗

January 05, 2026

Arcus Biosciences, a clinical-stage oncology innovator, reported significant insider selling as its stock capped a strong one-year return.

Via The Motley Fool

Performance

YTD	-0.4%	-0.4%
1 Month	-10.1%	-10.1%
3 Month	+65.4%	+65.4%
6 Month	+172.9%	+172.9%
1 Year	+56.0%	+56.0%

More News

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Arcus Biosciences

Via Business Wire

Why Did Arcus Biosciences Stock Slump 10% Today? ↗

December 12, 2025

Via Stocktwits

Analyst Expectations For Arcus Biosciences's Future ↗

October 29, 2025

Via Benzinga

Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ ↗

October 12, 2025

Via Stocktwits

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

December 12, 2025

From Arcus Biosciences

Via Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

December 09, 2025

From Arcus Biosciences

Via Business Wire

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

November 18, 2025

From Arcus Biosciences

Via Business Wire

Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan ↗

November 02, 2025

Via The Motley Fool

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

October 30, 2025

From Arcus Biosciences

Via Business Wire

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

October 30, 2025

From Arcus Biosciences

Via Business Wire

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

October 28, 2025

From Arcus Biosciences

Via Business Wire

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

October 19, 2025

From Arcus Biosciences

Via Business Wire

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months ↗

October 13, 2025

Via Benzinga

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

October 12, 2025

From Arcus Biosciences, Inc.

Via Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

October 09, 2025

From Arcus Biosciences

Via Business Wire

How Arcus Biosciences Aims To Take On Merck In Cancer Treatment ↗

October 07, 2025

Via Investor's Business Daily

Why Is Arcus Biosciences Stock Trading Higher On Monday? ↗

October 06, 2025

Via Benzinga

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

October 06, 2025

From Arcus Biosciences

Via Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

September 24, 2025

From Arcus Biosciences

Via Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

September 08, 2025

From Arcus Biosciences

Via Business Wire

Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗

September 03, 2025

Via Benzinga

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

September 02, 2025

From Arcus Biosciences

Via Business Wire

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

August 20, 2025

From Arcus Biosciences

Via Business Wire

Frequently Asked Questions

Is Arcus Biosciences, Inc. Common Stock publicly traded?

Yes, Arcus Biosciences, Inc. Common Stock is publicly traded.

What exchange does Arcus Biosciences, Inc. Common Stock trade on?

Arcus Biosciences, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for Arcus Biosciences, Inc. Common Stock?

The ticker symbol for Arcus Biosciences, Inc. Common Stock is RCUS on the New York Stock Exchange

What is the current price of Arcus Biosciences, Inc. Common Stock?

The current price of Arcus Biosciences, Inc. Common Stock is 23.20

When was Arcus Biosciences, Inc. Common Stock last traded?

The last trade of Arcus Biosciences, Inc. Common Stock was at 01/07/26 04:10 PM ET

What is the market capitalization of Arcus Biosciences, Inc. Common Stock?

The market capitalization of Arcus Biosciences, Inc. Common Stock is 2.48B

How many shares of Arcus Biosciences, Inc. Common Stock are outstanding?

Arcus Biosciences, Inc. Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.